Skip to main content
. Author manuscript; available in PMC: 2024 Feb 21.
Published in final edited form as: J Neurooncol. 2019 Sep 3;145(1):23–34. doi: 10.1007/s11060-019-03275-z

Fig. 5.

Fig. 5

miR-29a inhibits GBM cell and GSC derived xenograft growth. a, b GBM cells U87 (a) and GSC-267 cells (b) were infected with lentivirus encoding pre-miR-29a or pre-miR-control for 24 h and implanted into the brains of immunodeficient mice (n = 6). After 3 weeks, the mice were subjected to MRI scan and tumor volumes were calculated (c, d). e H&E staining of U87 xenografts generated from Lenti-control or pre-miR-29a U87 cells (red lines indicate the tumors). f Immunohistochemistry staining of U87 xenograft sections with antibodies against Ki67, CD31 and Cleaved Caspase 3. The data show that miR-29a inhibits in vivo GBM xenograft growth, reduces Ki67 and CD31 levels and enhances Cleaved Caspase 3 levels. *P < 0.05